Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 9/20 | 0.42 |
| ▸ | CBFB | Q13951 | 2/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.38 |
| ▸ | APP | P05067 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | MIF | P14174 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL187290 | 0.79 | CBFB (0.57) | METCBFBPDGFRBPDGFRAALDH1A1 | |
| SCHEMBL359222 | 0.77 | MET (0.47) | METCBFBPDGFRBPDGFRAAPP | |
| SCHEMBL370132 | 0.77 | CBFB (0.46) | METCBFBPDGFRBPDGFRAALDH1A1 | |
| SCHEMBL14926841 | 0.74 | ALDH1A1 (0.45) | METPDGFRBPDGFRAALDH1A1 | |
| SCHEMBL358693 | 0.73 | CNR1 (0.47) | METCBFBPDGFRBPDGFRAALDH1A1 | |
| SCHEMBL358992 | 0.73 | EGFR (0.42) | METCBFBAPPALDH1A1F2 | |
| SCHEMBL187431 | 0.73 | FBP1 (0.44) | METCBFBPDGFRBPDGFRAAPP | |
| SCHEMBL13619702 | 0.73 | MET (0.42) | METCBFBPDGFRBPDGFRAALDH1A1 | |
| SCHEMBL8560716 | 0.71 | TSHR (0.49) | METPDGFRBPDGFRAALDH1A1HPGD | |
| SCHEMBL160127 | 0.71 | CNR1 (0.43) | PDGFRBPDGFRAALDH1A1F2GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2593107-A1 | TYROSINE KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-05-22 | — | — | EP | disclosed |
| US-20130116231-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2013-05-09 | — | — | US | disclosed |
| US-20130116231-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2013-05-09 | — | — | US | disclosed |
| WO-2012009194-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-01-19 | — | — | WO | disclosed |
| WO-2012009194-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116231-A1 | TYROSINE KINASE INHIBITORS | ABL1, ERBB2, MET | MET 3/4885CBFB 1314/4885PDGFRB 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.